Investing.comCodex · 实盘不做把握 5/10
北京时间·🕒 发布 07-28 19:08:36时区推断·⟳ 抓取 07-28 19:09:10·⚡ 决策 07-29 08:02:27 +12h53m·90.5 天前
Cullinan计划2026年三季度启动CLN-049潜在注册性二期AML研究
FDA End-of-Phase 1反馈支持CLN-049进入潜在注册性Phase 2，方向利好Cullinan Therapeutics（CGEM.US）的管线推进。
📄 原文Investing.com↗ 原文
Cullinan plans phase 2 study for AML treatment CLN-049
Oil extends slide as U.S.-Iran talks raise hopes of lasting de-escalation CAMBRIDGE, Mass. - Cullinan Therapeutics, Inc…
不做 Cullinan Therapeutics（CGEM.US）
管线推进利好但非疗效读出、获批或商业化节点，短线可交易增量不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 medium · price-in 风险 medium ↗
关键理由
- FDA End-of-Phase 1反馈支持CLN-049进入潜在注册性Phase 2，方向利好Cullinan Therapeutics（CGEM.US）的管线推进。
- 但事件仍是临床开发路径确认，距读出、申请和商业化较远；AML美国年新诊断约2.3万人，仍需有效性和安全性数据支撑商业化概率。
主要风险
- 公司计划2026年四季度才披露剂量递增更新，当前没有新的注册性疗效读出或收入增量。
原文全文
展开原文 · 1,867 字
Oil extends slide as U.S.-Iran talks raise hopes of lasting de-escalation
CAMBRIDGE, Mass. - Cullinan Therapeutics, Inc. (NASDAQ:CGEM) announced today it received feedback from the U.S. Food and Drug Administration following an End-of-Phase 1 meeting for CLN-049, a FLT3xCD3 T cell engager being evaluated in patients with acute myeloid leukemia.
The company plans to initiate a potentially registrational Phase 2 study of CLN-049 in patients with relapsed/refractory AML in the third quarter of 2026, according to a press release statement. The study design incorporates a short dose-optimization phase with progression to a single-arm cohort at the recommended Phase 2 dose.
"The FDA’s feedback reinforces our confidence in the development strategy for CLN-049 and provides a clear path forward for potential regulatory approval," said Jeffrey Jones, Chief Medical Officer at Cullinan Therapeutics.
CLN-049 demonstrated clinical activity and a safety profile in patients with relapsed/refractory AML, as presented at the 2025 American Society of Hematology Annual Meeting. The company plans to share an update from the dose escalation portion of the study in the fourth quarter of 2026.
Cullinan will also initiate a Phase 1/2 study evaluating the combination of CLN-049, venetoclax, and azacitidine in patients with previously untreated AML.
CLN-049 is designed to target FLT3-expressing leukemia cells and binds to both mutated and non-mutated FLT3. The treatment has received Orphan Drug designation and Fast Track designation from the FDA for the treatment of relapsed/refractory AML.
Approximately 23,000 people are diagnosed with AML annually in the U.S., with about half as many deaths from the disease, according to the National Cancer Institute.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
CAMBRIDGE, Mass. - Cullinan Therapeutics, Inc. (NASDAQ:CGEM) announced today it received feedback from the U.S. Food and Drug Administration following an End-of-Phase 1 meeting for CLN-049, a FLT3xCD3 T cell engager being evaluated in patients with acute myeloid leukemia.
The company plans to initiate a potentially registrational Phase 2 study of CLN-049 in patients with relapsed/refractory AML in the third quarter of 2026, according to a press release statement. The study design incorporates a short dose-optimization phase with progression to a single-arm cohort at the recommended Phase 2 dose.
"The FDA’s feedback reinforces our confidence in the development strategy for CLN-049 and provides a clear path forward for potential regulatory approval," said Jeffrey Jones, Chief Medical Officer at Cullinan Therapeutics.
CLN-049 demonstrated clinical activity and a safety profile in patients with relapsed/refractory AML, as presented at the 2025 American Society of Hematology Annual Meeting. The company plans to share an update from the dose escalation portion of the study in the fourth quarter of 2026.
Cullinan will also initiate a Phase 1/2 study evaluating the combination of CLN-049, venetoclax, and azacitidine in patients with previously untreated AML.
CLN-049 is designed to target FLT3-expressing leukemia cells and binds to both mutated and non-mutated FLT3. The treatment has received Orphan Drug designation and Fast Track designation from the FDA for the treatment of relapsed/refractory AML.
Approximately 23,000 people are diagnosed with AML annually in the U.S., with about half as many deaths from the disease, according to the National Cancer Institute.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。